There are several different types of stability programs throughout the drug product life cycle, starting with the determination of the stability of the new drug, and proceeding through to the confirmation of the expiry date of the marketed batches as predicted by the development programs. Most of these programs generate data only very slowly and thus usually need to be carefully managed because of the cost benefit factors involved. Since products can change either because of imposed change control (e.g. for regulatory, quality or fiscal reasons) or external imposition (e.g. a supplier does not inform the firm of a change), it is usually necessary for many of the stability programs to be continuous in fulfilling the ultimate objective of always knowing the dating for the drug product with a high degree of confidence. This course discusses in detail the elements of the different types of developmental and market product programs and how they can be designed and operated. Because stability programs usually rapidly become expensive, particular attention is given as to how the principles of risk management can be applied to minimize cost.
Course Description:
The topics in this course include the following: • Objectives & basic approaches of stability testing • Stability testing throughout the product life cycle • Regulatory aspects: FDA, ICH, EU, Health Canada & USP • Meaning of Mean Kinetic temperature • Stability test methodology including updating & validation • Stability protocols • Program cost optimization & incorporating risk management • Detailed aspects of developmental programs • Detailed aspects of market batch programs • Role of Change Control • Statistical analysis of stability data • Handling the retain program • Treatment of OOS and OOT data & situations • Policy/SOP aspects
Course Leader:
Dr. Alan J. Smith
Dr. Alan J. Smith is an independent consultant in Pharmaceutical Quality and Technology. He was Corporate Director, Quality Affairs for the Whitehall Division of American Home Products (now Wyeth Division of Pfizer) following a career with the Ayerst Division. He has B.Sc. & Ph.D degrees from London Univ. (UK), and studied Business Administration at the Wharton School (Univ. Pennsylvania). He has experience in the chemical and pharmaceutical industries in research, analytical methods development, stability programs, regulatory affairs, quality control and corporate quality assurance. He has been chairman/speaker at many domestic and international conferences and has served on several industrial association committees including the PMA (now PhRMA) Committee on Stability and Expiration Dating and the ASTM Committee on Quality Systems. Dr Smith is a member of the Editorial Advisory Boards of Pharmaceutical Technology and Journal of GXP Compliance. In 1998 he was the recipient of the World Pharm award for services to the pharmaceutical industry. From 1996-2006 he served on the Board of Directors for Halsey Pharmaceuticals.
Who Should Attend:
This course will benefit those who need to know the elements of the various developmental and commercial stability programs that are involved in the life cycle of the typical drug product and how these elements are used in the design and operation of such programs. The material is particularly suitable for chemists, pharmacists, engineers and administrators working in the following areas: • R&D • Process Development • Analytical Development • QA • QC • Regulatory Affairs • Plant Operations • Corporate/Plant Management The course is applicable to personnel in Regulatory Agencies as well as those in drug product manufacturers, API manufacturers and commodity and outsource suppliers to the industry.